Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.52 |
| ▸ | CES1 | P23141 | 6/20 | 0.52 |
| ▸ | CES2 | O00748 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10582003 | 0.85 | PAOX (0.47) | FAAHCES1CES2MEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL6560336 | 0.83 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL27116615 | 0.81 | FAAH (0.48) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL28216388 | 0.80 | FAAH (0.47) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL27473837 | 0.80 | FAAH (0.55) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL27473405 | 0.78 | FAAH (0.57) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL1286762 | 0.77 | FAAH (0.61) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL11105639 | 0.77 | FAAH (0.61) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL2573096 | 0.77 | FAAH (0.61) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL638951 | 0.77 | FAAH (0.61) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987540-B2 | Crystalline solids of 3-palmitoyl-amido-1,2-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane and methods of making and using the same | GERON CORPORATION (US) | 2024-05-21 | — | — | US | disclosed |
| CN-114901269-A | Crystalline solids of 3-palmitoyl-amido-1, 2-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane and methods of making and using the same | 美国杰龙生物医药公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20210147342-A1 | CRYSTALLINE SOLIDS OF 3-PALMITOYL-AMIDO-1,2-PROPANEDIOL AND 3-PALMITOYL-AMIDO-2-HYDROXY-1-DIMETHOXYTRIPHENYLMETHYLETHER-PROPANE AND METHODS OF MAKING AND USING THE SAME | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2021-05-20 | — | — | US | disclosed |
| WO-2021086754-A1 | CRYSTALLINE SOLIDS OF 3-PALMITOYL-AMIDO-1,2-PROPANEDIOL AND 3-PALMITOYL-AMIDO-2-HYDROXY-1-DIMETHOXYTRIPHENYLMETHYLETHER-PROPANE AND METHODS OF MAKING AND USING THE SAME | GERON CORPORATION (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987540-B2 | Crystalline solids of 3-palmitoyl-amido-1,2-propanediol and 3-palmitoyl-amido-2-hydroxy-1-dimethoxytriphenylmethylether-propane and methods of making and using the same | SPTLC3, PLD2, SPTLC2 | FAAH 69/4885CES1 393/4885CES2 959/4885 |
| US-20210147342-A1 | CRYSTALLINE SOLIDS OF 3-PALMITOYL-AMIDO-1,2-PROPANEDIOL AND 3-PALMITOYL-AMIDO-2-HYDROXY-1-DIMETHOXYTRIPHENYLMETHYLETHER-PROPANE AND METHODS OF MAKING AND USING THE SAME | SPTLC3, PLD2, SPTLC2 | FAAH 69/4885CES1 393/4885CES2 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.